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Background: The use of cognitive enhancement (CE) by means of pharmaceutical agents has been the subject of
intense debate both among scientists and in the media. This study investigates several drivers of and obstacles to
the willingness to use prescription drugs non-medically for augmenting brain capacity.
Methods: We conducted a web-based study among 2,877 students from randomly selected disciplines at German
universities. Using a factorial survey, respondents expressed their willingness to take various hypothetical CE-drugs;
the drugs were described by five experimentally varied characteristics and the social environment by three varied
characteristics. Personal characteristics and demographic controls were also measured.
Results: We found that 65.3% of the respondents staunchly refused to use CE-drugs. The results of a multivariate
negative binomial regression indicated that respondents’ willingness to use CE-drugs increased if the potential drugs
promised a significant augmentation of mental capacity and a high probability of achieving this augmentation.
Willingness decreased when there was a high probability of side effects and a high price. Prevalent CE-drug use among
peers increased willingness, whereas a social environment that strongly disapproved of these drugs decreased it.
Regarding the respondents’ characteristics, pronounced academic procrastination, high cognitive test anxiety, low
intrinsic motivation, low internalization of social norms against CE-drug use, and past experiences with CE-drugs
increased willingness. The potential severity of side effects, social recommendations about using CE-drugs, risk
preferences, and competencies had no measured effects upon willingness.
Conclusions: These findings contribute to understanding factors that influence the willingness to use CE-drugs. They
support the assumption of instrumental drug use and may contribute to the development of prevention, policy, and
educational strategies.
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Researchers describe the attempt by healthy individuals to
augment their cognitive capacities (e.g. increasing concen-
tration, alertness, or memory) with prescription drugs –
also known as cognitive enhancement (CE) – as a
continuing social trend. These studies discuss the use of
different drugs and drug classes as potential enhancers,
such as stimulants (e.g., methylphenidate, amphetamines,
or modafinil), antidementives (e.g., memantin, piracetam,
or donepezil) and antidepressants (e.g., citalopram, fluox-
etine or, sertraline) [1-5]. Such drugs are usually pre-
scribed to treat diseases including narcolepsy, shift work
sleep disorder, attention deficit hyperactivity disorder, de-
mentia, Alzheimer’s disease, depression, anxiety disorders,
and so on.
Research on attitudes towards, prevalence of, and mo-
tives for using cognitive enhancers has often focused on
students (cf. [6]). Their temptation to use such drugs is
presumed to be high because mental capacity is essential
for academic success and future career opportunities.
North American studies report lifetime prevalence rates of
prescription stimulant use for CE as ranging from 3 to 11%
[7]. Studies of German students showed a lifetime preva-
lence rate of 0.8% for prescription stimulant use for CE [8]
and of 4.5% for multiple types of prescription medication
used for CE [9]. This implies that a significant number of
students are already exposing themselves to the risk of side
effects and long-term health consequences. These risks in-
clude headaches, addiction, insomnia, fatal arrhythmias,
excitotoxicity, reduced appetite, hypertension, anxiety, jit-
teriness, and personality changes (e.g. [10-14]). Not all po-
tential side effects and negative health consequences of
CE-drug use are presently known and there are additional
risks of drug-drug interactions, overdose, and the use of
impure substances [15-18].
While a body of literature exists, for example, on the
general, non-medical (mis-)use of different types of pre-
scription medications (including motivations such as losing
weight, enhancing performance, getting high, improving
mood, etc.) [17,19-26], researchers have only recently
begun to direct their attention to the drivers of and obsta-
cles to the decision to use prescription drugs specifically
for the enhancement of cognitive performance (e.g.,
[6,8,9,27,28]). Our research has been informed by and has
built upon the first body of literature. But one significant
limitation of these previous studies is that they present
solely correlations between socio-demographics and the
use of (or willingness to use) CE-drugs, with few theory-
driven explanations. Consequently, behavioral patterns,
motives, and variables that influence the willingness to use
CE-drugs still remain to be identified (cf. [25-27,29]).
The theoretical basis of our research rests upon socio-
logical and economic decision-making theories [30,31]
that propose that individuals (a) want to attain certaingoals such as academic success, but (b) they also have
beliefs about the possibilities for or restrictions to achiev-
ing these goals. These possibilities and restrictions include
the characteristics of the drugs, personal characteristics,
and influences from the social environment. Based on
their evaluation of the situation, individuals (c) choose a
behavior that best fits their individual preferences, per-
ceived opportunities, and constraints. Consequently, we
assume that individuals instrumentally decide whether or
not to use drugs (e.g., [9,27,32]). Recent research found
evidence for this assumption of instrumental CE-drug use,
as individuals use such drugs as means to achieve certain
goals (e.g., [9,33]).
Drug characteristics
It can be assumed that individuals consider the charac-
teristics of CE-drugs before choosing to take them or
not. On the one hand, individuals might ponder the de-
gree and probability of enhancement in order to deter-
mine whether the drugs would satisfy their needs. On the
other hand, they may be unwilling to take risks that are
too great and therefore also take the severity and probabil-
ity of side effects into consideration. Different individuals
might be willing to pay different amounts. The influence
of such drug characteristics upon respondents’ willingness
to take them has not been sufficiently investigated or rep-
licated. For example, in a study by Castaldi et al. [6], risks
and benefits were measured with a single question, there-
fore the various individual influences of these characteris-
tics could not be determined. For health campaigns, it
might be useful to investigate the degree to which poten-
tial users take health risks into consideration (cf. [6]) and
are affected by potentially exaggerated benefits [33].
One study found that willingness to use a fictitious CE-
drug increased in proportion to higher enhancement
effect [33]. Similar results have been found for the non-
medical use of prescription stimulants [19,21]. This result
supports the assumption of an instrumental use of CE-
drugs [9,32,33]. The effect of increased cognitive abilities
on the willingness to use CE-drugs has rarely been investi-
gated, however. Sattler et al. [33] showed that a higher
probability of enhancement effects increased respondents’
willingness to use a fictitious drug. This probability re-
flects the fact that the impact of CE-drugs is dependent
on factors such as the physical condition of individuals or
their responsiveness to medical treatment [11,12,34]. We
propose the following hypothesis (H):
HEnhancement effect (magnitude): The higher the magnitude
of enhancement effect, the higher the willingness to use
CE-drugs.
HEnhancement effect (probability): The higher the probability
of enhancement, the higher the willingness to use
CE-drugs.
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ity of side effects serve as obstacles to drug use (e.g.,
[9,19,23,28,33,35]). CE-drugs can harm individuals by
means of potential side effects and health risks. Avoiding
such harm and refraining from drugs with more severe
and likely side effects is also in keeping with our pre-
sumption of instrumental CE-drug use. Thus, we expect
the following:
HSide effects (severity): The higher the severity of side
effects, the lower the willingness to use CE-drugs.
HSide effects (probability): The higher the probability of side
effects, the lower the willingness to use CE-drugs.
Some evidence concerning the effect of price has been
obtained from students who stated that price is in fact a
condition for using licit/illicit stimulants for purposes of
CE and that they would be more willing to use them if
they were inexpensive [35]. While research on illicit drugs
has taken into account the elastic effect of price upon de-
mand [36,37], to our knowledge the effects of price on de-
mand for CE-drugs remains unknown. We assume that
individuals also take the price of CE-drugs into account
when deciding for or against using such drugs:
HDrug price: The higher the price, the lower the
willingness to use CE-drugs.
Social environment
Prior studies of illicit drug use [38,39] and the non-
medical use of prescription stimulants such as amphet-
amines and methylphenidates [19,20] have demonstrated
that social contexts affect the decision to consume such
drugs. Social context may also affect the willingness to
use CE-drugs in several ways. Potential social pressure
may motivate CE-drug use, resulting in contagion ef-
fects. Learning effects can also influence decisions, as for
example in the transmission of information about the
pros and cons of CE-drug intake. Furthermore, social
control can affect the willingness to use CE-drugs, in the
sense that when others become aware of an individual’s
use of CE-drugs they may punish the user with punitive
behavior such as social disapproval.
Peer prevalence
CE-drug use by others has been discussed as an induce-
ment to their use [2,40]. Individuals who refrain from
using them may have relative disadvantages [28,40] be-
cause they may need to work harder to keep up with
users. A recent study [28] also found the same contagion
effect in the case of a fictitious CE-drug. However, Franke
et al. [35] found that the majority of respondents (66%)
would (very) likely refrain from using licit/illicit stimulants
for purposes of CE even if others used them. Prevalent useof drugs may also be an indication of these drugs having a
good risk-benefit ratio [28] and/or being morally accept-
able (cf. [41,42]). Thus, we expect the following:
HPeer prevalence: The higher the peer prevalence, the
higher the willingness to use CE-drugs.
Social suggestions
Research suggests that advice from the social network
stimulates CE-drug use [6], while Franke et al. [35] found
that only a few respondents stated that they would think
about using licit/illicit stimulants for CE if their employers
recommended them. We expect the following:
HSocial suggestions: The more positive advice received
concerning CE-drug use, the higher the willingness to
use CE-drugs.
Social disapproval
Social control in terms of social disapproval (cf. [43-45])
might present an obstacle to the willingness to use CE-
drugs. Strong disapproval by others may lower willing-
ness to use CE-drugs. Some studies have been able to
confirm this hypothesis for the non-medical use of pre-
scription stimulants [19,20]. Social disapproval indicates
that CE conflicts with social/group norms. Violating
such norms may lead to costs in the form of informal
punishment [44,45], such as exclusion from the group.
Thus, we expect the following:
HSocial disapproval: The higher the level of social
disapproval, the lower the willingness to use CE-drugs.
Personal characteristics
Personal characteristics, such as a lack of competencies
(e.g., [24-26]) or motivation, the tendency to procrastin-
ate, and the experience of cognitive test anxiety (CTA)
[9], may be factors in explaining the willingness to use
CE-drugs because they may produce a demand for
pharmaceutical agents. These characteristics may ham-
per academic performance, (e.g., [46-49]), and CE-agents
may help students to cope with related (subjectively per-
ceived) deficits and their negative consequences. Similar
assumptions can be derived from the Strain Theory,
which has been used to explain the non-medical use of
prescription stimulants [22]. Most of these variables
have not been investigated in terms of the willingness to
use CE-drugs.
The question has been raised of whether CE-drug users
aim to enhance their performance above average or to
achieve an average level of performance [50]. It can be ar-
gued that students with low self-efficacy see themselves as
less skilled or less successful [51] and attempt to attain
success by other means. Consequently, they may have a
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perceived lack of competence and to catch up to their
peers (cf. [9,25]). Several studies (e.g., [19,24,26]) have
found that lower grades and lower self-assessed compe-
tencies were associated with increased non-medical use of
stimulants. Consequently, we expect the following:
HCompetencies: The higher the self-assessed competencies,
the lower the willingness to use CE-drugs.
The tendency to take risks may be influential because
CE-drug use has potential negative effects on health and is
therefore a risky behavior. Prior research has shown that
risk-averse individuals are more likely to refrain from CE-
drug use [9]. Therefore, we expect the following:
HRisk attitudes: The higher the tendency to take risks, the
higher the willingness to use CE-drugs.
Students might instrumentally use drugs because of
their ‘subjectively attributed or real beneficial effects’ in
coping with CTA and avoiding its negative consequences
(cf. [9,32]). These consequences occur because CTA nega-
tively affects test preparation and test-taking due to im-
paired working memory [49,52]. Although no effect of
CTA was found in a small-scale investigation using a con-
venience sample of students from a German vocational
school [27], a recent study [9] found that higher levels of
CTA increased the frequency of CE-drug use. We expect
the following:
HCognitive Test Anxiety: The higher the level of CTA, the
higher the willingness to use CE-drugs.
Study motivation
For intrinsically motivated students, academic achievement
and learning are ends in themselves, and these students
achieve satisfaction from mastering a task (e.g., [53-56]).
Taking CE-drugs might undermine their sense of personal
achievement and reduce their satisfaction (cf. [57]). Empir-
ical studies reveal that intrinsically motivated students are
less competitive and less focused on good grades (e.g.,
[56,58]), and thus that gaining competitive advantage over
fellow students by taking CE-drugs might be less import-
ant. Therefore, intrinsic motivation is expected to be a pro-
tective factor against willingness to use CE-drugs:
HStudy motivation: The more students are intrinsically
motivated in their studies, the lower their willingness
to use CE-drugs.
Academic procrastination
Like CTA, academic procrastination results in time pres-
sure and decreased academic performance [46,47]. Thispressure can be seen as a crucial source of strain [22].
Some students attempt to cope with this strain by cheat-
ing or plagiarizing [59], whereas for other students, it
can be assumed that CE-drug use is an attractive coping
strategy:
HAcademic procrastination: The more often students
procrastinate, the higher their willingness to use
CE-drugs.
CE-drug use is also connected to social norms such as
fairness and authenticity [2,60,61]. While social norms
have been found to be strong predictors of the con-
sumption of illicit drugs such as marijuana [62,63] and
the non-medical use of prescription stimulants [19], they
have rarely been investigated in studies focusing specific-
ally on CE-drugs [33], which is another research gap
[60]. Violating internalized social norms against CE-drug
use might result in internal penalties (i.e. psychological
costs) and we expect this to impede the willingness to use
CE-drugs (cf. [33,43,64]). Thus, we expect the following:
HInternalized social norms: The more strongly norms against
CE-drug use are internalized, the lower the willingness
to use CE-drugs.
Previous studies [9,19,23] have shown that prior drug
use increased the likelihood of prescription drug use for
non-medical reasons including CE. This effect has been
interpreted as a result of preferences related to previous
decisions and conditions [9,65,66]. This finding may also
reflect the fact that students are likely to repeat behavior
that was ‘experienced as either successful or less burden-
some’ after passing habituation processes [9,32,67]. Per-
sonal experiences with the non-medical use of prescription
drugs have been found to reduce perceived side effects,
increase perceived benefits, and increase subsequent use,
(e.g., [23,24,68]). Consequently, we expect the following:
HPrior CE-drug use: Prior CE-drug use increases willing-
ness to use CE-drugs.
It is essential to obtain insight into the factors that in-
fluence the willingness to use CE-drugs in order to de-
velop prevention, policy, and educational strategies [25].
Such strategies may be needed due to the potential social
problems related to CE-drug use, such as (a) the social
pressure of abstainers to take CE-drugs to keep up with
users, (b) the harmful side effects for users, and (c) societal
burden upon the health care system. While the current
prevalence of CE-drug use is relatively low (see above),
several researchers have forecasted an increased consump-
tion of such substances (e.g., [3,6,69,70]). Therefore, be-
sides only monitoring the development of prevalence
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potential use of such drugs. Previous research on the
(illicit) use of tobacco, amphetamines, and marijuana, for
example, has shown that willingness measures can be used
to predict subsequent behavior (e.g., [71,72]). The use of a
willingness measure allowed us to experimentally vary and
test the influence of several hypothetical characteristics of
CE-drugs and of the social context upon the decision-
making process. We were also able to investigate potential
future scenarios and their impact on the respondents’ will-
ingness to use CE-drugs, such as a significant amount of
performance enhancement with or without side effects.
To sum up, our study aims to investigate the influence of
personal and contextual factors as well as drug character-
istics (see hypotheses below) on students’ willingness to
use CE prescription medication without any medical ne-
cessity (see Figure 1). Thus, we address some limitations
of prior studies (such as small-scale convenience samples
or a focus on limited sets of factors).
Methods
Participants and survey method
In January 2011, we conducted a self-administered, fully
anonymous web survey during the biannual longitu-
dinal FAIRUSE survey on study conditions and aca-
demic cheating (cf. [9])a. Four German universities were
randomly selected for the study. Within these univer-
sities, we randomly selected 175 students from 14 ran-
domly drawn academic disciplines with nstudents > 175.
Furthermore, we sampled 300 students from all otherl
l
Figure 1 Factors influencing the willingness to use CE-drugs.disciplines with nstudents < 175. Our survey was sent ini-
tially to a total of 11,000 students (2,750 per university)
from 138 disciplines.
The second wave of this study – which is the basis for
this paper – invited the participation of students who a)
had completed the survey in the first wave, b) did not
finish their studies, c) did not change their university, or
d) dropped out of their university. We therefore sent pre-
notification letters by mail to 5,048 students who met
these criteria; the letters explained the study’s purpose and
data protection strategy and included a protection dec-
laration. Approximately one week later, we emailed
invitations and personal access codes for the survey
followed by up to two reminder emails. At the end of
the survey, students could choose a 5 Euro incentive in
the form of money sent by mail or via PayPal, vouchers
for an online retailer, or donations to UNICEF or Am-
nesty International.
Our response rate from the second wave of 69.1%
(n = 3,486) is similar to the rates of other studies in this
field [24,73,74]. Complete responses for all analyzed
variables were available for 2,877 respondents. To test
whether missing data caused by item non-responses and
dropout influenced our results, we used a multiple imput-
ation procedure by chained equations [75]. Because results
did not change significantly (results available upon re-
quest), listwise deletion was used. Two out of five (39.3%)
participants were male (see Table 1 for all demographic in-
formation). Age was measured in intervals of two years to
provide more privacy. The median age was 22–23 years.ll
Table 1 Descriptive statistics for the demographic
variables
Variable Total Percent of
this sample
Percent of the
population
Gender
▪ Female 1,753 60.7 53.5
▪ Male 1,134 39.3 46.5
Age
▪ <18 1 0.0 0.0
▪ 18-19 37 1.3 4.3
▪ 20-21 744 25.8 21.3
▪ 22-23 864 29.9 23.8
▪ 24-25 646 22.4 20.8
▪ 26-27 282 9.8 12.6
▪ 28-29 143 5.0 6.9
▪ 30-31 68 2.4 3.6
▪ 32-33 32 1.1 2.0
▪ 34-35 24 0.8 1.2
▪ 36-37 7 0.2 0.7
▪ 38-39 7 0.2 0.6
▪ 40-41 7 0.2 0.5
▪ >41 25 0.9 1.5
Field of study
▪ Sports 92 3.2 3.5
▪ Linguistic and cultural studies 943 32.7 25.9
▪ Legal, economic, and social
sciences
309 10.7 31.6
▪ Mathematics and natural
sciences
1,135 39.3 23.3
▪ Human medicine and health 70 2,4 6.5
▪ Agriculture, forestry, and
nutritional sciences
85 2.9 1.0
▪ Engineering 165 5.7 6.5
▪ Arts and science of art 88 3.1 1.8
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sented 39.2% of the respondents.Ethics statement
Our research was guided by the principles formulated in
the WMA Declaration of Helsinki. No ethics approval is
needed for social science research in Germany as long as
it does not refer to matters regulated by law, such as the
German Medicine Act (AMG), the Medical Devices Act
(MGP), the Stem Cell Research Act (StFG), or the
Association’s Professional Codes of Conduct. Therefore,
no approval was needed for our study. According to
paragraph 28 of the Data Protection Act of North Rhine
Westphalia, we used a fully anonymous research design.Several means have been employed to ensure the volun-
tariness, confidentiality, and anonymity of our survey,
which were emphasized in all communications with re-
spondents: The partnering universities never had access
to response data, and the researchers never had access
to any of the respondents’ personal data. Furthermore,
secure sockets layer (SSL) protocols were used to protect
answers while responding. Participants were informed
about the anonymity and purpose of the survey via pos-
tal letters, in all subsequent e-mails, and on the first sur-
vey page. Therefore, participation can be understood as
a conclusive action. All our procedures and data collec-
tion were approved by the legal services of Bielefeld Uni-
versity and supervised by an official data protection
officer.Predictors assessed using a factorial survey design
We applied a factorial survey [76,77] in which respon-
dents evaluated descriptions (so-called vignettes) of a
person facing the decision of whether or not to take a
hypothetical CE-drug (cf. [28,33], see the discussion sec-
tion for limitations of this approach). We experimentally
varied five characteristics (dimensions) of this drug
(magnitude, probability of enhancement effect, severity,
probability of side effects, and drug price), and three
characteristics of the social environment (peer preva-
lence, social disapproval, and social suggestions; see
Table 2). Each of these eight dimensions consists of
three levels, implying a total of (38 = 6,561 possible com-
binations, of which 600 were chosen via D-efficient sam-
pling, (e.g., [78]). D-efficient designs are constructed by
using an algorithm specifying a sample characterized by
minimal correlation between the dimensions and, at the
same time, maximal variance and balance of the fre-
quency of the vignette levels. The sampling procedure
was done with SAS software. Each respondent was ran-
domly assigned to one of the 600 vignettes. Each single
vignette was rated multiple times by different respon-
dentsb. After reading the vignette, the respondents were
asked the following question: ‘Would you consume the
drug if you were in her position?’ They rated their will-
ingness to use the drug on a 10-point scale ranging from
‘strongly against use’ (0) to ‘strongly in favor of use’ (9).Predictors assessed with the survey
Risk attitudes
Respondents were asked the following question: ‘Are you
generally a person who is fully prepared to take risks, or
do you try to avoid taking risks?’ They rated their risk
attitudes on an 11-point scale ranging from ‘not at all
willing to take risks’ (1) to ‘very much willing to take
risks’ (11). This measure has been experimentally vali-
dated and showed high stability in prior research [79].
Table 2 Descriptive statistics for the independent metric variables measuring personal characteristics
Variable Response options Min Max Mean Standard deviation
Left anchor Right anchor
Risk attitudes Not at all willing to take risks Very much willing to take risks 1 11 5.47 2.283
Academic procrastination Very seldom Very often 1 6 2.77 0.978
Study motivation Do not agree at all I agree completely 1 6 4.68 1.074
Cognitive test anxiety (CTA) Not true at all Completely true 1 4 3.07 0.718
Competencies Very difficult Very easy 1 5 3.27 0.585
Internalized social norms Absolutely moral Absolutely not moral 1 7 5.58 1.714
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The cognitive dimension of the German version of the
Test Anxiety Inventory was used to assess CTA [80].
We selected five items (e.g., ‘I am thinking about the
consequences of failing’) based on factor loadings in pre-
vious studies [81]. We used a four-point scale ranging
from ‘not true at all’ (1) to ‘completely true’ (4). The in-
ternal consistency (α = 0.87) was acceptable compared to
the original scale (α = 0.91; [82]).
Academic procrastination
We used the Questionnaire for Academic Procrastin-
ation (QAP) [83]. Conceptually, this instrument refers to
the intention-action gap, or the problem of not turning
intentions into the desired actions (cf. [84,85]). It covers
different stages of task processing. The frequency of
eight behaviors (e.g., ‘Even if I intend to finish a univer-
sity assignment, I do not do it.’) was rated on a six-point
scale ranging from ‘very seldom’ (1) to ‘very often’ (6).
The internal consistency was good (α = 0.93).
Competencies
Students rated their academic skills using six items (e.g.,
‘handling a typical question in their subject’) from the
‘Evaluation in Higher Education: Self-Assessed Compe-
tences’ instrument (HEsaCom; [86]) on a five-point scale
from ‘very difficult’ (1) to ‘very easy’ (5). The alpha score
(0.78) of this scale was acceptable but slightly below the
original scale. Students were also asked for their grades.
Due to a higher number of missing values in this meas-
ure and similar effects on the willingness to use CE-
drugs (results not discussed here), we used the self-rated
competencies measure only.
Study motivation
Intrinsic study motivation was assessed by asking the
question, ‘Why do you learn and study in your main sub-
ject?’ (cf. [87,88]). Three items, such as ‘I learn and work
because the study content corresponds to my personal
preferences’, were rated on a six-point scale ranging from‘do not agree at all’ (1) to ‘I agree completely’ (6). The
scale had an internal consistency of α = 0.91.
Internalized social norms
Respondents disclosed their internalization of social
norms concerning CE-drug use by answering the ques-
tion [33], ‘How do you personally evaluate the use of
prescription drugs to enhance work performance with-
out any medical necessity? I think the use is…’ and three
items: ‘before an examination’, ‘during an examination’,
and ‘in general for university studies’. Responses were
rated on a seven-point scale ranging from ‘absolutely
moral’ (1) to ‘absolutely not moral’ (7). Our measure re-
vealed a high internal consistency (α = 0.94).
Prior CE-drug use
Prior use was assessed with the question, ‘There are stu-
dents who enhance their cognitive efficiency using pre-
scription medicine without any medical necessity. Have
you ever done that?’ and five response options: ‘never’ (0),
‘last 30 days’ (1), ‘last 30 days to 6 months’ (2), ‘6 months
to 1 year’ (3), and ‘>1 year’ (4) (cf. [9]). To distinguish
non-users from users and because of the low prevalence,
we deployed a binary coding (portion of non-users =
97.2%; users = 2.8%). This prevalence rate of prescription
drug use for CE is low but nonetheless still within the
range of prevalence rates found in prior German studies
[8,27,40]. The results, however, are not entirely compar-
able, due to the different sampling strategies used and dif-
ferent definitions of CE-drugs, for example. [5,89].
Statistical analysis
Within the factorial survey, almost two-thirds (65.3%) of
the respondents strongly refused to take the presented CE-
drug, whereas the others were more willing to consume
the drug. Due to overdispersion in the data (Mean = 1.08;
SD = 2.019), we applied a multivariate negative binomial
regression model that produces more efficient and less-
biased estimates than ordinary least squares models [90] or
Poisson models. Wald tests were applied to assess the
Table 3 Vignette dimensions and levels used in this
study: experimental variation of five drug characteristics
and three characteristics of the social environment
Dimension Levels
Peer prevalence A student considers using a prescription drug
to enhance her memorization skills for her
exam preparation. From a medical point
of view, this is not necessary. This student
knows that
▪ none
▪ every second
▪ every one
of her friends or acquaintances uses such
substances.
Social suggestions She
▪ never
▪ sometimes
▪ very often
gets suggestions from others to try such
means.
Magnitude of
enhancement effect
By taking such drugs, she hopes to increase
the amount of memorized information by
▪ 5 percent
▪ a factor of two
▪ a factor of three
compared to her normal state.
Probability of
enhancement effect
From a recently published study, she knows
that that the effect occurs with a
▪ 5
▪ 50
▪ 100
percent chance.
Probability of side
effects
This study also reported that
▪ one of 1,000,000 users
▪ one of 1,000 users
▪ every user
Severity of side effects developed
▪ very light
▪ moderate
▪ very strong
depression. Further side effects are unknown.
Drug price Someone can provide her with a package of
10 pills for
▪ free.
▪ 20 Euros.
▪ 100 Euros.
This is enough for 20 learning hours.
Table 3 Vignette dimensions and levels used in this
study: experimental variation of five drug characteristics
and three characteristics of the social environment
(Continued)
Social disapproval The use of such drugs would cause
▪ no
▪ moderate
▪ very strong
criticism in her environment
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Results
Drug characteristics
Table 3 shows that the respondents’ willingness to take
the drug increased by a factor of 1.329 or 32.9% (z = 3.25;
p < 0.001) when the described drugs tripled the amount of
memorized information compared to a 5% increase. A
doubled amount had no effect (z = 0.11; p = 0.914). An
enhancement effect occurring with a probability of 50%
(z = 2.83; p = 0.005) or 100% (z = 3.86; p < 0.001) signifi-
cantly increased the willingness compared to a probability
of 5%. The severity of side effects had no significant ef-
fect. However, when every user had to fear side effects
compared to only one of 1,000,000 users, respondents
were less willing to use the drug (z = −5.16; p < 0.001).
Compared to this latter category, no deterrent effect of
side effects occurred in one of 1,000 users (z = −0.57;
p = 0.567). A price of 100 Euros for 10 pills also reduced
the willingness to use a pill compared to free pills
(z = −4.22; p < 0.001).
Social environment
We found greater willingness to use the drug when every
second peer (z = 2.95; p = 0.003) or every peer used it
(z = 3.19; p = 0.001) compared to a situation in which no
friends or acquaintances used such drugs. Social sugges-
tions had no effect, but students were deterred from usage
when they received very strong social criticism regarding
usage compared to no criticism (z = −3.87; p < 0.001).
Personal characteristics
We found that risk attitudes (z = 0.72; p = 0.470) and
competencies (z = 0.67; p = 0.501) had no influence on
the responses. Individuals who tended to procrastinate
(z = 2.86; p = 0.004), less intrinsically motivated individuals
(z = −3.15; p = 0.002), and students with higher CTA scores
(z = 6.05; p < 0.001) were more willing to use CE-drugs.
Higher levels of norm internalization against CE-drug use
reduced the willingness to use such drugs (z = −17.85;
p < 0.001). Respondents who had already used CE-drugs
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had never used such drugs (z = 6.85; p < 0.001).
Demographic controls
Gender (z = −0.65; p = 0.515) and age (z = −1.42; p =
0.156) did not affect the respondents’ willingness to use a
CE-drug. We found the lowest willingness among sports
students compared to engineering students (z = 2.28;
p = 0.023).
Discussion
By analyzing the influence of distinct types of potential
factors explaining the willingness to use CE-drugs, this
study contributes in multiple ways to an understanding
of the drivers and obstacles related to CE-drug use.
Drug characteristics
As previously found [33] and as assumed in our hypoth-
esis (HEnhancement effect (magnitude)), respondents were more
willing to use CE-drugs when their enhancing effect was
very strong. However, to date, the magnitude of the per-
formance enhancement of available CE-drugs is small to
moderate for healthy users [14]. A tripled amount of
memorable information might be not achievable today,
but testing this potential future scenario reveals interest-
ing insights about future trends or exaggerated expecta-
tions. Similar to another study [33] and in line with
HEnhancement effect (probability), the probability of enhance-
ment effects increased respondents’ willingness to use
these drugs. The effects found here indicate that individ-
uals consider the magnitude and probability of enhance-
ment when facing the decision to use CE-drugs, which
supports the assumption of an instrumental CE-drug
use [9,32,33].
Previous research, (e.g., [9,23]), has found that more
significant side effects are associated with a lower will-
ingness to engage in non-medical drug use. In studies
similar to ours, one study found that side effects such as
increased severity of headaches [33] reduced the willing-
ness to use a fictitious CE-drug. A second study found
that the possibility of more severe side effects decreased
the respondents’ willingness to use drugs compared to
the possibility of only mild side effects [28]. In this study,
we could not replicate this deterrent effect. Therefore,
HSide effects (severity) has to be rejected in our study. The rea-
sons for this should be investigated in future research.
However, in line with the instrumental use of CE-drugs
and with HSide effects (probability), a high likelihood of side ef-
fects decreases the willingness to use CE-drugs. This find-
ing conforms to prior research [28,33,35].
As hypothesized (HDrug price), we found that a high
price decreased the willingness to use CE-drugs. This
finding is in line with economic studies on the supply
and demand of illicit drugs (see for instance [36,37]) andconfirms the finding from another CE study [35] that
the price is important.
Social environment
According to HPeer prevalence, our results show greater
willingness when more peers use CE-drugs. Another
study has also provided evidence of such a contagion ef-
fect [28]. But Franke et al. [35] showed that only a mi-
nority of respondents (7.5%) would also consume licit/
illicit stimulants for purposes of CE when friends did so.
Suggestions by others to use CE-drugs did not alter
the respondents’ willingness to take CE-drugs, conse-
quently HSocial suggestions has to be rejected. Another sur-
vey has shown that only 5.7% of the respondents would
use CE-drugs if employers recommended their use. Fu-
ture research can investigate whether recommendations
by others than employers are (more) influential.
In line with HSocial disapproval, the willingness to use
CE-drugs was lower when others strongly disapproved
of their use. This can be interpreted as a social control
effect. Respondents appear to seek to avoid the cost of
informal punishment by others.
Personal characteristics
While several studies (e.g., [24,26]) have found that (self-
assessed) performance measures were associated with in-
creased non-medical use of prescription drugs, we did
not find such an effect from self-assessed competencies
(cf. [68] and [9] for 6-months use frequency) on the will-
ingness to use a CE-drug. Therefore, HCompetencies has to
be rejected for our data.
No effect was found from risk attitudes. This finding
contradicts HRisk attitudes and prior research that found
that risk-averse individuals used CE-drugs less often [9].
Future research should clarify this ambivalence.
In line with a recent study [9] and HCognitive Test Anxiety,
we found that higher levels of CTA increased the will-
ingness to use CE-drugs. This can be understood as a
coping strategy to deal with CTA and its negative conse-
quences. However, the findings of another investigation
among students from a German vocational school [27]
were not supportive of this hypothesis. The meaningful-
ness and interpretability of this investigation is limited,
as it is based on a small-scale convenience sample.
We found that students with higher intrinsic motiv-
ation to study were less willing to take CE-drugs. Thus,
HStudy motivation is confirmed by our data. Our results in-
dicate that such motivation can be seen as a protective
factor against CE-drug use, because CE-drug use might
conflict with achieving satisfaction through hard work.
Our study is the first to show that academic procras-
tination increases the willingness to use CE-drugs.
Consequently, HAcademic procrastination was confirmed. Our
underlying assumption was that individuals try to cope
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using CE-drugs.
We confirmed the result of a prior study on CE-drugs
[33] by showing that a stronger internalization of social
norms decreases the willingness to use a CE-drug. This
finding also confirms HInternalized social norms. The strong
effect found here implies that internalized norms are a
major factor in the decision-making process about mor-
ally questionable behavior and that internal penalties oc-
curring in the case of norm violations might be very
costly to the individual.
Similar to a prior study on CE-drug use [9] and to our
hypothesis (HPrior CE-drug use), we found that prior CE-
drug use increased the willingness to use CE-drugs. This
effect can have several meanings: it can be interpreted as
behavior guided by habits or as a result of preferences
related to previous decisions and conditions of decision-
making. Future research should determine which inter-
pretation is accurate.
Similar to several previous studies on the non-medical
use of prescriptions, we found no significant gender dif-
ferences (e.g., [24,25,74]) although other studies have re-
ported higher levels of non-medical drug use among
men [24,26,91]. Further research is required to clarify a)
whether gender differences exist and b) what causes po-
tential differences.
No age effects occurred in our study (cf. [26,28]) al-
though some studies [17,92] have found that older stu-
dents admitted to having used non-prescription drugs
more often. An investigation of the reasons for this find-
ing is left for future research.
Sports students revealed the lowest values regarding
willingness to use CE-drugs, whereas the highest values
were found among engineers. However, prior studies
[8,91,93] found no clear pattern in terms of academic
discipline. Therefore further investigation is needed.
Limitations of the study
This study has several limitations. Because not all sampled
students participated, potential selective non-response
could bias the results. However, our response rate of 69.1%
is similar to previous studies in this field [8,29,73]. We also
assessed the influence of selective dropout on the study re-
sults. To do so, we calculated sampling weights with infor-
mation about the proportions of each gender, age group,
and academic discipline from the basic population of the
four universities (see Column 4 in Table 1) and reran the
regression model presented in Table 4 [94]. There were no
significant changes in the results, indicating that sample
composition biases did not influence the interpretation of
the results with respect to our hypotheses.
The question about the willingness to use CE-drugs
might be seen as sensitive due to the normative dimen-
sion of CE-drug use (cf. [28]). For sensitive questions,non-anonymous surveys may result in underreporting
[95,96]. As described in the methods section, our study
was fully anonymous; answers were protected via SSL
protocols, and an official data protection officer moni-
tored adherence to the data protection strategy. Data se-
curity principles were emphasized in all communications
with respondents. Generally, respondents in web surveys
reveal higher levels of sensitive information than respon-
dents in computer-assisted telephone interview surveys
[97]. One indication of the confidentiality of the survey
is that only 19 participants (0.5%) refrained from answer-
ing the question about their willingness to use CE-drugs.
Moreover, due to the hypothetical nature of factorial sur-
veys, responses are less prone to response bias than direct
questioning surveys [98-100]. Finally, we tested whether
perceptions of anonymity regarding the survey influenced
the reported willingness, but we found no effects (results
are available upon request).
Our study utilized a willingness measure to use CE-
drugs. Such measures do not fully correspond to actual
behavior. The conditions presented in the vignettes might
differ from the factors actually influencing a respondent’s
decisions. However, there is evidence from research on
the (illicit) use of tobacco, amphetamines, or marijuana,
for example, that willingness measures are factors that do
influence behavior (e.g., [71,72]). Our approach allowed us
to experimentally vary and test the influence of several
hypothetical characteristics of CE-drugs and of the social
context in the decision-making process. Consequently, po-
tential and interesting future scenarios could be investi-
gated as well such as a high magnitude of performance
enhancement or a social environment very friendly to CE.
Another advantage of willingness measures is their lower
sensitivity. Thus, fewer refusals or distorted answers can
be expected (e.g., [72]). Furthermore, when attempting to
study behavior several problems need to be considered; it
can, for example, be problematic to explain past behavior
by means of factors measured after the occurrence of this
behavior because such factors might change over time.
Panel designs as well might overlook these changes [43].
However, investigating the hypotheses of our study with
behavioral measures in future research is worthwhile.
Another potential limitation is that we only investigated
university students in one country. Cultural differences,
the legal status of drugs, and drug availabilities vary across
countries and may affect the willingness to use CE-drugs
(e.g., [8,9]). Therefore, future studies should replicate our
study in other cultural contexts.
Conclusion and implications
By analyzing various drivers of and obstacles to the will-
ingness to use CE-drugs, this study aimed to increase our
understanding of decisions regarding their use. As such, it
provides a necessary supplement and corrective to the
Table 4 Multivariate negative binomial regression model
on the willingness to use a CE-drug (n = 2,887)
IRRa 95% CIb
Drug characteristics
Magnitude of enhancement effect
(Ref. 5 percent):
▪ a factor of two 1.010 [0.849,1.201]
▪ a factor of three 1.329** [1.120,1.577]
Probability of enhancement effect
(Ref. 5 percent):
▪ 50 percent 1.287** [1.081,1.533]
▪ 100 percent 1.392*** [1.177,1.646]
Severity of side effects (Ref. very light
depression):
▪ moderate depression 0.924 [0.781,1.093]
▪ very strong depression 0.881 [0.746,1.041]
Probability of side effects (Ref. one of
1,000,000 users):
▪ one of 1,000 users 0.955 [0.815,1.119]
▪ every user 0.634*** [0.533,0.754]
Drug price (Ref. free):
▪ 20 Euros 1.118 [0.955,1.310]
▪ 100 Euros 0.683*** [0.572,0.815]
Social environment
Peer prevalence (Ref. none):
▪ every second 1.287*** [1.089,1.522]
▪ every one 1.321** [1.113,1.568]
Social suggestions (Ref. never):
▪ sometimes 0.887 [0.749,1.051]
▪ very often 1.071 [0.907,1.265]
Social disapproval (Ref. no criticism):
▪ moderate criticism 0.926 [0.788,1.090]
▪ very strong criticism 0.713*** [0.600,0.846]
Personal characteristics
Risk attitudes 1.012 [0.980,1.045]
Academic procrastination 1.112** [1.034,1.196]
Study motivation 0.897** [0.839,0.960]
Cognitive test anxiety (CTA) 1.383*** [1.245,1.535]
Competencies 1.048 [0.915,1.199]
Internalized social norms 0.673*** [0.644,0.702]
Prior CE-drug use 2.409*** [1.873,3.097]
Demographic variables
Male (Ref. female) 0.949 [0.812,1.110]
Agec 0.969 [0.928,1.012]
Field of study (Ref. sports):
▪ Linguistics & cultural studies 1.260 [0.792,2.004]
▪ Legal, economic, & social sciences 1.237 [0.763,2.006]
▪ Mathematics & natural sciences 1.261 [0.797,1.995]
Table 4 Multivariate negative binomial regression model
on the willingness to use a CE-drug (n = 2,887) (Continued)
▪ Human medicine & health 1.272 [0.710,2.279]
▪ Agriculture, forestry, & nutritional sciences 1.285 [0.716,2.307]
▪ Engineering 1.845* [1.089,3.126]
▪ Arts & science of art 1.669 [0.981,2.839]
Log-pseudolikelihood (full model) −3566.2
Log-pseudolikelihood (base model) −3848.1
*p < 0.05, **p < .01, ***p < .001 (Wald tests, robust standard errors).
a Adjusted Incidence Rate Ratios (IRR).
b Confidence Intervals (CI).
c Age was treated as a metric variable (see Table 2 for the 14
measured categories).
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assume that CE-drug use [6,69] will increase in the future,
but also many factors influencing the use of CE-drugs
have not yet been investigated (or their effects have not
been replicated). Not understanding the potential causes
of CE-drug use is and remains an obstacle in developing
policy, intervention, and prevention. We have found that
several factors increase the willingness to use CE-drugs,
whereas other factors decrease it, and some have no effect.
Thus, we can generally confirm our assumption that CE-
drug use is an instrumental behavior in the sense of a ra-
tional choice (cf. [9,28,32]). Several factors may increase
the perceived usefulness of CE-drug consumption and
therefore may turn it into a preferred strategy. For ex-
ample, students may expect these drugs to help them cope
with certain personal deficits or restrictions in achieving
academic success (cf. [9]). Their use could be associated
with the anticipation of rewards or the avoidance of
negative consequences, including costs such as relative
disadvantages when many peers are assumed to medic-
ally augment their performance. Other constraints on
the willingness to use CE-drugs instrumentally were
also considered, such as the potentially deterrent effect
of high prices, the high likelihood of side effects, or
strong social disapproval.
Our results have several implications that can be utilized
for interventions and policy regulations. For instance, will-
ingness to use CE-drugs only increased if the magnitude
of the enhancement was likely and extraordinary. How-
ever, people can be informed that such medication seems
not to exist at the moment (e.g., [14]) to avoid exaggerated
perceptions and to reduce the inclination to use CE-drugs.
Castaldi et al. [6] suggest health campaigns to inform the
public about the negative consequences of CE-drugs. This
idea is supported by the deterrent effect of very probable
side effects. Because internalized social norms against CE-
drug use decreased the willingness to use CE-drugs, pol-
icymakers could consider means to strengthen such
norms, such as defining them as misconduct and includ-
ing their disaffirmation in university honor codes [cf. 33].
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can be employed to reduce risky self-medication. The will-
ingness to engage in CE-drug use can be described as an
instrumental coping strategy to address the anticipated
negative effects of CTA (cf. [9]). Means to reduce CTA
(e.g., behavioral or cognitive-focused interventions) or its
negative consequences (e.g., social support) could decrease
the benefits of CE-drug use (cf. [101,102]). Because the
willingness to take CE-drugs decreases with increasing
intrinsic study motivation, a deterrent to drug use could
involve fostering mastery goal orientation among students,
for example by increasing autonomy in selecting learning
contents or encouraging students to take intellectual risks
instead of penalizing mistakes (cf. [55]). Further research
should investigate the influence of the suggested means of
regulating CE-drug use.
Endnotes
aTwo variables (risk attitudes and intrinsic study mo-
tivation) were assessed in wave 1 of this biannual study,
and all the others were measured in wave 2. For the sake
of brevity, we only describe details for the second wave
here (see [9] for details about wave 1).
bWithin our design, we also investigate rare cases or
hypothetical (future) scenarios to explore their theoretic-
ally interesting effects (e.g., drugs tripling the amount of
memorized information but causing very strong depres-
sion in every user). None of these is illogical or unimagin-
able. The very low numbers of students who refused to
answer the vignette (n = 18) or dropped out on this page
(n = 1) can be seen as indicators that our vignettes were
easy to answer.
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